Figure 5.
In the subset of RCTs with data on patients with and without liver metastases, the similar benefit with VEGFi was seen in patients with liver metastases vs. those without liver metastases for OS. (A) Forest plot and pooled HRs for OS in patients with liver metastases (HR = 0.86; 95% CI, 0.74–0.99; moderate heterogeneity: I2 = 56%, p = 0.010). (B) Forest plot and pooled HRs for OS in patients without liver metastases (HR = 0.89; 95% CI, 0.80–0.98; low heterogeneity: I2 = 17%, p = 0.28) [27,34,35,36,42,43,44,45,46,47,49,50].